CBPD-409

Overview

CBPD-409 is an orally active PROTAC degrader for CBP/p300 , with DC 50 of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC 50 s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 ( HY-108435 ); Blue: CRBN/cullin 4A Thalidomide ( HY-14658 ); Black: Linker).

Application

Products | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > PROTAC | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Histone Acetyltransferase | Products > Signaling Pathways > PROTACs

Product Information

• Catalog No.: HY-158113
• CAS No.: 3037549-86-0
• Molecular Formula: C46H52F2N10O5
• Molecular Weight: 862.97
• Purity: 98.29%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (2.90 mM); Clear solution
• Availability: In-stock

Source

Original product source